ARPO Aerpio Pharmaceuticals Inc

DGAP-News: Emerging Product Design Company Pegmatis Inc. Joins the Canadian Pavilion at CES 2019

DGAP-News: Pegmatis Inc. / Key word(s): Miscellaneous
Emerging Product Design Company Pegmatis Inc. Joins the Canadian Pavilion at CES 2019

06.11.2018 / 13:00
The issuer is solely responsible for the content of this announcement.


Toronto, Ontario--(Newsfile Corp. - November 6, 2018) - Pegmatis, a rapidly expanding product design and engineering company, is delighted to have been selected as part of the Canadian Trade Mission at the 2019 Consumer Electronics Show (CES) in Las Vegas NV., January 8-11 2019. An established Canadian leader in this fast growing, highly competitive sector, Burlington-based Pegmatis, founded in 2016, has built a reputation for delivering unique, high-performance product solutions in demanding form factors.

'This is the right time for Pegmatis to move into international markets, and CES is the first step. Canada's global profile as a hot technology centre and investment in the advanced manufacturing supercluster aligns well with Pegmatis' expertise bringing quality advanced consumer electronics products from concept to scale. There's an explosion in increasingly sophisticated consumer electronic products. We think there's a great opportunity for us - and the country - to establish ourselves as leaders,' says Gary Puppa, Director of Business Development.

'We'll be talking to industry, competitors - getting a feel for where the industry is going and ensuring we stay at the bleeding edge. There's momentous change afoot, and Canada is in the midst of renaissance. This country's technology is second to none; its appetite for innovation is immense. We want the world to know it, and we want Pegmatis to be a big part of Canada's innovation story.'

Visit Pegmatis at the Canadian Pavilion (#1021) during CES or connect with us to learn more about the products we're building and how we can help bring your vision to life.

About CES

CES is the world's largest trade show for the business of consumer technologies and next-generation innovations. Taking place in Las Vegas NV., annually, CES attracts aver 170,000 attendees and 3,900 exhibiting companies from 150 countries.

About Pegmatis

Pegmatis delivers comprehensive product design and engineering services for embedded device platforms, Internet of Things, mobile, cloud and web. Hardware, software, firmware and strategic consulting: Pegmatis thrives on challenging projects that demand imagination, technical dexterity and a relentless commitment to excellence. Pegmatis' work can be found in the products of start ups and Fortune 500 companies alike. Founded in 2016 and based in Burlington, Ontario, Pegmatis is an emerging force in Canada's technology community.

###

Contact:
Gary Puppa
Director of Business Development
905 962 2962

newsinfo.php?i=40823&f=169

Click on, or paste the following link into your web browser, to view the associated documents /release/40823


06.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: Pegmatis Inc.
Canada

 
End of News DGAP News Service

741959  06.11.2018 

fncls.ssp?fn=show_t_gif&application_id=741959&application_name=news&site_id=research_pool
EN
06/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch